Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of ...
Futures rose after the Dow Jones rose for a seventh straight session Thursday. Nvidia chipmaker Taiwan Semi reported strong ...
Final results from RMCL-002 Phase 2 trial to be presented in the Late Breaking Clinical Trials session at the European Renal Association (ERA) Congress on May 25, 2024. An investor call to provide a ...